We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

Immatics (NASDAQ:IMTX) shares surged 11.7% after early trial results of IMA203 cell therapy showed a 56% response rate in ...

I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision ...

Summit Therapeutics' recent stock sell-off reflects regulatory uncertainty rather than drug failure. Click here to read an ...

Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

Simris Group AB (publ), through its wholly owned subsidiary Simris Biologics GmbH, has signed a non-binding concept sheet with a EU based biopharmaceutical company specializing in the development of ...

Shares of Vera Therapeutics, Inc. (VERA) were in the spotlight on Tuesday morning after the company announced that it has ...

Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human ...

UniQure said it has aligned with the FDA on components of a statistical analysis plan for a registrational trial of AMT-130.

Phase 1 results disclosed Monday indicate the company’s protein-degrading drug can affect a tough-to-reach target called ...

AMT-130 has been granted the FDA’s Regenerative Medicine Advance Therapy (RMAT) designation and Breakthrough Therapy designation, the first therapy for Huntington’s disease to receive an RMAT ...

STEM Education in K-12 Market size was Valued at USD 306.62 million in 2024 and is projected to grow at a CAGR of 364% from 2025 to 2033 ...